The first and only C5a receptor antagonist indicated in the treatment of ANCA-associated vasculitis (GPA/MPA)1*
Mechanism of action†
PrTAVNEOS® reduces the pro-inflammatory effects of C5a
Adapted from the Product Monograph.2
Avacopan reduces the pro-inflammatory effects of C5a on vascular inflammation, including:2
- Neutrophil activation and migration
- Adherence to sites of small blood vessel inflammation
- Vascular endothelial cell retraction and increased permeability
Avacopan does not inhibit:2
- The formation of the membrane attack complex (MAC)
- The terminal complement complex (TCC), which is important in fighting infections with encapsulated bacteria
*
Comparative clinical significance has not been established.
†
Clinical significance is unknown.
ANCA = anti-neutrophil cytoplasmic autoantibody; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis.
References:
1. Data on file. Otsuka Canada Pharmaceutical Inc.
2. TAVNEOS Product Monograph. Otsuka Canada Pharmaceutical Inc.